Carolinas Pathology Group, Levine Cancer Institute, Charlotte, NC, USA.
Charlotte Radiology, Carolinas Medical Center, Charlotte, NC, USA.
Mod Pathol. 2015 May;28(5):670-6. doi: 10.1038/modpathol.2014.159. Epub 2014 Nov 21.
Flat epithelial atypia of the breast commonly co-exists with atypical ductal hyperplasia, lobular neoplasia, and indolent forms of invasive carcinomas such as tubular carcinoma. Most patients with pure flat epithelial atypia on core biopsy undergo surgical excision to evaluate for carcinoma in the adjacent breast tissue. Studies to date have reported varying upgrade rates with most recommending follow-up excision. These studies have often lacked detailed radiographic correlation, central review by breast pathologists and information regarding the biology of the carcinomas identified upon excision. In this study, we report the frequency of upgrade to invasive carcinoma or ductal carcinoma in situ in excision specimens following a diagnosis of pure flat epithelial atypia on core biopsy. Radiographic correlation is performed for each case and grade/receptor status of detected carcinomas is reported. Seventy-three (73) core biopsies containing pure flat epithelial atypia were identified from our files, meeting inclusion criteria for the study. In the subsequent excision biopsies, five (7%) cases contained invasive carcinoma or ductal carcinoma in situ and seventeen (23%) contained atypical ductal hyperplasia or lobular neoplasia. All of the ductal carcinoma in situ cases with estrogen receptor results were estrogen receptor positive and intermediate grade. The invasive tumors were small (pT1a) hormone receptor-positive, HER2-negative, low-grade invasive ductal or tubular carcinomas with negative sentinel lymph-node biopsies. No upgrades were identified in the 14 patients who had all of their calcifications removed by the stereotactic core biopsy. Our rate of upgrade to carcinoma, once cases with discordant imaging are excluded, is at the lower end of the range reported in the literature. Given the low upgrade rate and indolent nature of the carcinomas associated with flat epithelial atypia, case management may be individualized based on clinical and radiographic findings. Excision may not be necessary for patients without remaining calcifications following core biopsy.
乳腺平坦上皮不典型增生常与非典型导管增生、小叶肿瘤以及惰性浸润性癌如管状癌共存。大多数在核心活检中诊断为单纯平坦上皮不典型增生的患者需要进行手术切除以评估对侧乳腺组织中的癌。迄今为止的研究报告了不同的升级率,大多数建议进行随访切除。这些研究往往缺乏详细的影像学相关性、乳腺病理学家的中心审查以及关于切除后发现的癌的生物学信息。在本研究中,我们报告了在核心活检中诊断为单纯平坦上皮不典型增生后,切除标本中升级为浸润性癌或导管原位癌的频率。对每个病例进行影像学相关性分析,并报告检测到的癌的分级/受体状态。从我们的档案中确定了 73 例(73 例)包含单纯平坦上皮不典型增生的核心活检符合本研究的纳入标准。在随后的切除活检中,有 5 例(7%)病例含有浸润性癌或导管原位癌,17 例(23%)含有非典型导管增生或小叶肿瘤。所有具有雌激素受体结果的导管原位癌病例均为雌激素受体阳性和中等级别。侵袭性肿瘤体积较小(pT1a),激素受体阳性、HER2 阴性、低级别浸润性导管癌或管状癌,前哨淋巴结活检阴性。在所有的钙化均通过立体定向核心活检切除的 14 例患者中,未发现升级。在排除了影像学不一致的病例后,我们的癌升级率处于文献报道的较低范围。鉴于与平坦上皮不典型增生相关的癌具有低升级率和惰性特征,病例管理可以根据临床和影像学表现个体化进行。对于核心活检后无残留钙化的患者,切除可能不是必需的。